YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis
Cells · 10.09.2024 · 13 (18) · 1519
DOI: 10.3390/cells13181519 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 10.09.2024. Verfasst von Kostas A Papavassiliou und 5 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, Medical School, 'Sotiria' Hospital, National and Kapodistrian University of Athens, 11527 Athens…. Hauptthemen laut MEDLINE: Signal Transduction, Pulmonary Fibrosis, YAP-Signaling Proteins. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a severe, irreversible lung disease characterized by progressive scarring, with idiopathic pulmonary fibrosis (IPF) being the most prevalent form. IPF’s pathogenesis involves repetitive lung epithelial injury leading to fibroblast activation and excessive extracellular matrix (ECM) deposition. The prognosis for IPF is poor, with limited therapeutic options like nintedanib and pirfenidone offering only modest benefits. Emerging research highlights the dysregulation of the yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling pathway as a critical factor in PF. YAP and TAZ, components of the Hippo pathway, play significant roles in cell proliferation, differentiation, and fibrosis by modulating gene expression through interactions with TEA domain (TEAD) transcription factors. The aberrant activation of YAP/TAZ in lung tissue promotes fibroblast activation and ECM accumulation. Targeting the YAP/TAZ pathway offers a promising therapeutic avenue. Preclinical studies have identified potential treatments, such as trigonelline, dopamine receptor D1 (DRD1) agonists, and statins, which inhibit YAP/TAZ activity and demonstrate antifibrotic effects. These findings underscore the importance of YAP/TAZ in PF pathogenesis and the potential of novel therapies aimed at this pathway, suggesting a new direction for improving IPF treatment outcomes. Further research is needed to validate these approaches and translate them into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First University Department of Respiratory Medicine, Medical School, 'Sotiria' Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Laboratory of Clinical Biochemistry, Medical School, 'Attikon' University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
ORCID-Profile: Kostas A Papavassiliou, Amalia A Sofianidi, Vassiliki A Gogou, Antonios N Gargalionis, Athanasios G Papavassiliou
Zitieren
APA
Papavassiliou, K. A., Sofianidi, A. A., Spiliopoulos, F. G., Gogou, V. A., Gargalionis, A. N., & Papavassiliou, A. G. (2024). YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis. Cells, 13(18), 1519. https://doi.org/10.3390/cells13181519
Vancouver
Papavassiliou KA, Sofianidi AA, Spiliopoulos FG, Gogou VA, Gargalionis AN, Papavassiliou AG. YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis. Cells. 2024;13(18):1519. doi:10.3390/cells13181519
BibTeX
@article{Papavassiliou2024,
author = {Papavassiliou, Kostas A and Sofianidi, Amalia A and Spiliopoulos, Fotios G and Gogou, Vassiliki A and Gargalionis, Antonios N and Papavassiliou, Athanasios G},
title = {YAP/TAZ Signaling in the Pathobiology of Pulmonary Fibrosis},
journal = {Cells},
year = {2024},
volume = {13},
number = {18},
pages = {1519},
doi = {10.3390/cells13181519}
}
EUVIMED